A 28-year-old woman from Mumbai with newly diagnosed smear-positive pulmonary TB has completed 2 weeks of HRZE therapy and reports good symptom improvement. Repeat sputum smear microscopy at 2 weeks shows persistent AFB positivity. She is adherent to therapy and denies any missed doses. What is the most appropriate next step?

Explanation

## Clinical Context This patient has smear-positive TB with clinical improvement but persistent AFB on sputum smear at 2 weeks. The key question is whether this represents treatment failure or slow bacterial clearance. ## Sputum Conversion Timeline in TB **High-Yield:** Sputum smear conversion (negativity) in drug-susceptible TB typically occurs: - 50–80% of patients by 2 weeks of HRZE - 90% by 4–6 weeks - Delayed conversion does NOT automatically indicate drug resistance if the patient is adherent and clinically improving **Key Point:** Persistent AFB positivity at 2 weeks in an adherent, clinically improving patient is NOT immediate evidence of treatment failure. The standard definition of TB treatment failure is: - Sputum smear or culture positive at 5 months or later during therapy, OR - Sputum conversion followed by reversion to positivity ## Management Algorithm ```mermaid flowchart TD A[Smear-positive TB on HRZE]:::outcome --> B{Adherent?}:::decision B -->|No| C[Counsel on adherence, DOT]:::action B -->|Yes| D{Clinical improvement?}:::decision D -->|No| E[Assess for complications, drug resistance]:::action D -->|Yes| F{Smear at 2 weeks}:::decision F -->|Negative| G[Continue HRZE, standard course]:::action F -->|Positive| H[Continue HRZE, repeat smear at 4-6 weeks]:::action H --> I{Smear at 4-6 weeks}:::decision I -->|Negative| J[Continue standard therapy]:::action I -->|Positive| K[Obtain culture & DST, assess resistance]:::action K --> L[Modify regimen if MDR/XDR confirmed]:::action ``` ## Why Continue HRZE and Recheck at 4 Weeks? | Finding | Interpretation | Action | |---|---|---| | Smear positive at 2 weeks, clinically improving, adherent | Slow but ongoing bacterial clearance (common) | Continue HRZE, recheck at 4–6 weeks | | Smear positive at 4–6 weeks, clinically improving, adherent | Still may represent slow response; culture/DST needed | Obtain sputum culture & DST; continue therapy pending results | | Smear positive at 5+ months | Treatment failure (per WHO definition) | Assess for MDR-TB; switch to second-line regimen | **Clinical Pearl:** Sputum smear microscopy is less sensitive than culture for detecting persistent viable bacilli. A patient may have negative smears but positive culture (or vice versa). Persistent smear positivity at 2 weeks with clinical improvement and good adherence does not mandate immediate regimen change. ## Why Not the Other Options? **Option 0 (Switch to second-line immediately):** Treatment failure is defined as sputum positivity at 5 months or later, not at 2 weeks. Switching regimens prematurely in a clinically improving, adherent patient is inappropriate and exposes her to more toxic second-line drugs without evidence of resistance. **Option 2 (Add ethambutol):** The standard HRZE regimen already includes four drugs (isoniazid, rifampicin, pyrazinamide, ethambutol). Adding a fifth drug is not indicated for slow sputum conversion in an adherent patient. Ethambutol is already part of the intensive phase in most TB regimens. **Option 3 (CT and bronchoscopy):** Imaging and invasive procedures are not indicated in a clinically improving patient. These would be considered if there were signs of complications (hemoptysis, pneumothorax, empyema) or if sputum remained positive at 5+ months despite therapy. [cite:Harrison 21e Ch 205]